UroGen Pharma Ltd.
URGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $654,035 | $524,489 | $500,878 |
| - Cash | $90,039 | $92,904 | $104,033 | $171,987 |
| + Debt | $128,352 | $125,921 | $124,949 | $123,387 |
| Enterprise Value | – | $687,052 | $545,405 | $452,278 |
| Revenue | $27,482 | $0 | $20,254 | $24,565 |
| % Growth | – | -100% | -17.5% | – |
| Gross Profit | $24,204 | $0 | $17,924 | $22,094 |
| % Margin | 88.1% | – | 88.5% | 89.9% |
| EBITDA | -$25,768 | $0 | -$38,886 | -$26,490 |
| % Margin | -93.8% | – | -192% | -107.8% |
| Net Income | -$33,347 | $0 | -$43,843 | -$37,512 |
| % Margin | -121.3% | – | -216.5% | -152.7% |
| EPS Diluted | -0.69 | -1.05 | -0.92 | -0.8 |
| % Growth | 34.3% | -14.1% | -15% | – |
| Operating Cash Flow | -$42,270 | -$39,825 | -$42,024 | -$13,619 |
| Capital Expenditures | -$87 | -$141 | -$44 | -$115 |
| Free Cash Flow | -$42,357 | -$39,966 | -$42,068 | -$13,734 |